A clinical overview of GLP-1 receptor agonist therapy at TRIA — how it works, what to expect, and how to get the most from your treatment.
GLP-1 (Glucagon-Like Peptide-1) medications are a class of injectable drugs that mimic a naturally occurring hormone in your gut. That hormone — GLP-1 — is normally released when you eat, signaling your body to produce insulin, slow digestion, and reduce appetite. In people who struggle with obesity or metabolic dysfunction, this signaling system is often impaired.
GLP-1 receptor agonists restore and amplify this signal. They don't force your body to do something unnatural — they enhance a mechanism your body already uses, but does not use efficiently enough.
GLP-1 therapy works best when it is part of a broader metabolic strategy. The medication creates the window — nutrition, movement, and lifestyle choices determine what you build inside it.
TRIA works with both semaglutide and tirzepatide. The right choice depends on your medical history, weight loss goals, tolerance, and budget. Your clinician will guide this decision during your initial consultation.
| Semaglutide Ozempic · Wegovy |
Tirzepatide Mounjaro · Zepbound |
|
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GLP-1 + GIP receptor agonist |
| Injection frequency | Once weekly | Once weekly |
| Avg. weight loss | ~10–15% body weight (clinical trials) | ~15–22% body weight (clinical trials) |
| FDA approved for weight loss | ✓ (Wegovy — 2.4mg) | ✓ (Zepbound — 2026) |
| Blood sugar control | Significant improvement | Greater improvement (dual action) |
| Cardiovascular benefit | ✓ Documented (SUSTAIN trials) | Under ongoing investigation |
| Starting dose | 0.25 mg/week, titrated up | 2.5 mg/week, titrated up |
| Common side effects | Nausea, decreased appetite, fatigue | Similar — often milder GI profile |
Your TRIA clinician will conduct a thorough health history review and order appropriate labs before prescribing any GLP-1 medication.
Most side effects from GLP-1 medications are gastrointestinal in nature and are directly related to the drug's mechanism — slowing digestion. They are most prominent during dose escalation and typically diminish as your body adjusts. They rarely require stopping treatment.
Usually mild to moderate. Typically occurs in the first few weeks after a dose increase. Eating smaller, lower-fat meals and avoiding eating rapidly reduces nausea significantly. Your clinician may slow the titration schedule if symptoms are bothersome.
This is the intended effect — but it requires attention to nutrition quality. Even when eating less, adequate protein and micronutrient intake remains critical. Do not skip meals; eat smaller, nutrient-dense portions.
Changes in bowel habits are common, particularly early in treatment. Stay well-hydrated (64–80 oz water daily), maintain fiber intake, and report persistent symptoms to your clinician.
Some patients experience mild fatigue early in treatment, often related to reduced caloric intake. Ensuring adequate protein and staying hydrated typically resolves this. Report significant fatigue to your clinician.
Minor redness, bruising, or tenderness at the injection site is normal. Rotate injection sites (abdomen, thigh, upper arm) with each dose to minimize reactions.
GLP-1 medications create a powerful metabolic window — but what you do inside that window determines your long-term outcome. Poor nutrition choices during treatment can lead to muscle loss, nutrient deficiency, and weight regain if the medication is ever stopped. The following principles apply specifically to patients on GLP-1 therapy.
Rapid weight loss on GLP-1 therapy can include loss of lean muscle mass if protein intake is inadequate. This is the most important nutritional priority.
Smaller stomach capacity on GLP-1 therapy makes meal composition critical. Quality over quantity is the governing principle.
Dehydration is a real risk on GLP-1 therapy due to reduced appetite for fluids and potential GI fluid losses.
One of the most important — and often overlooked — considerations with GLP-1 therapy is the potential for muscle loss alongside fat loss. Rapid weight reduction without adequate protein and resistance training can reduce lean body mass, which slows metabolism and makes weight maintenance harder long-term.
Patients who achieve the best long-term outcomes are those who use GLP-1 therapy to build sustainable lifestyle habits. Medication alone does not produce lasting change. The goal at TRIA is to address the metabolic root cause while helping you establish the patterns that protect results for life.
Your consultation includes a medical history review, discussion of your goals, and labs if indicated. Once cleared, your clinician will prescribe the most appropriate medication and starting dose, with a titration schedule tailored to your tolerance.
Both Semaglutide and Tirzepatide come in pre-filled auto-injector pens. Your TRIA clinician will walk you through proper injection technique at your first dispensing visit. Injections go into the abdomen, thigh, or upper arm — rotate sites each week.
Clinical studies show that most patients regain a significant portion of lost weight after stopping GLP-1 therapy, particularly if lifestyle changes have not been made. This is why TRIA emphasizes building sustainable habits during treatment — they are your long-term protection.
GLP-1 medications can interact with certain diabetes medications (increasing hypoglycemia risk) and may affect the absorption of oral medications due to slower gastric emptying. Your clinician will review your full medication list during your consultation.
No. While GLP-1 medications were originally developed for type 2 diabetes management, they are FDA-approved for chronic weight management in non-diabetic patients with obesity or weight-related health conditions. TRIA's program is designed specifically for metabolic weight loss — not diabetes treatment.
Follow-ups at TRIA typically occur at 4–6 weeks and then every 3 months. We assess your response, review weight and body composition changes, check labs as indicated, adjust dosing, address any side effects, and reinforce lifestyle strategies.
Ozempic and Wegovy both contain semaglutide — Ozempic was originally approved for diabetes, Wegovy at a higher dose for weight loss. Mounjaro and Zepbound both contain tirzepatide — Mounjaro for diabetes, Zepbound for weight loss. The active ingredient is the same in each pair; the approved dose and indication differ.
Compounded versions of these medications have been available during shortage periods. Your clinician will advise on the current landscape and whether compounded versions are appropriate and available for your situation.
Yes — and at TRIA, this is often a powerful combination. Hormonal imbalances (particularly low estrogen, progesterone, and testosterone) can directly impair metabolism and make weight loss significantly harder. Optimizing hormone levels alongside GLP-1 therapy often produces synergistic results in both weight loss and overall well-being.
Yes. TRIA accepts Cherry, CareCredit, and Alphaeon for flexible payment plans. GLP-1 medications may be covered by insurance if you meet qualifying criteria. Ask our team for details.
"The most common thing I hear from patients who start GLP-1 therapy is that they finally feel in control around food for the first time in years. That is not willpower — that is biology being corrected."
Violet Magiera, DNP, APRN-FPA, FNP-C
Book a GLP-1 consultation with Violet or Anna. We'll review your health history, goals, and candidacy — and design a protocol that fits your life.